New study shows how ribociclib works in real life for advanced breast cancer patients
NCT ID NCT07363434
First seen Jan 27, 2026 · Last updated May 15, 2026 · Updated 14 times
Summary
This study looked at how well the drug ribociclib works in Indian women with a certain type of advanced breast cancer (HR+, HER2-). Researchers collected data from medical records of 335 patients across 18 hospitals in India. The goal was to see how long the drug kept the cancer from getting worse and to check its safety in everyday use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis
East Hanover, New Jersey, 07936, United States
Conditions
Explore the condition pages connected to this study.